Michael J. Fitzpatrick
52 IP cases indexed. Covers patent matters.
Cases Presided Over
52 cases indexed | Page 1 of 2
Duration Media v.Rich Media Club LLC
The PTAB affirmed all ten claims of the ’329 ad‑viewability patent, finding Duration Media failed to prove obviousness over Krassner, Badros, and Harkins. Claim constructions on “render,” “replacement advertisement,” and the “in‑response‑to” step were adopted.
Garmin International, Inc. et al. v.Saris Equipment, LLC
Garmin and Saris Equipment jointly moved to end the IPR over patent 10,434,394 after reaching a settlement. The Board granted the motion, terminating the proceeding and sealing the settlement agreement.
Skechers U.S.A., Inc. v.Nike, Inc.
Nike's footwear knitting patent survived Skechers' IPR challenge. The Board found no unpatentable claims after rejecting the obviousness arguments based on Reed and Nishida references.
Zepp Health Corporation v.University of Connecticut
Zepp Health and the University of Connecticut settled their IPR dispute over Patent 10,278,647 B2. The Board granted a joint motion to terminate, ending the proceeding before trial.
ZEPP HEALTH CORPORATION v.Worcester Polytechnic Institute
Zepp Health filed an IPR against Worcester Polytechnic Institute’s patent 10,653,362. The parties settled the dispute before a trial, and the Board terminated the proceeding, keeping the settlement confidential.
USAA Federal Savings Bank v.PACid Technologies, LLC
USAA Federal Savings Bank and PACid Technologies settled their patent dispute, leading to the termination of three IPRs before any trial was instituted.
lululemon usa inc. et al. v.Nike, Inc.
The PTAB issued a Final Written Decision finding all 21 challenged claims unpatentable. The Board determined that the prior art (Nishida and Zuckerman) anticipated or rendered obvious the claimed textile manufacturing methods, specifically regarding simultaneous knitting and planar configuration.
Inari Agriculture, Inc. v.Corteva Agriscience LLC et al.
The PTAB Board upheld the validity of U.S. Patent No. 8,901,378 B2 after finding that the TC1507 germplasm was publicly available prior to the application's filing date. The Board concluded that this availability satisfied priority requirements and prevented Barbour from qualifying as prior art under § 102.
Avanos Medical, Inc. v.Stratus Medical, LLC
The PTAB issued a Final Written Decision finding all 27 challenged claims unpatentable based on obviousness over prior art (Racz, Fitz, Lee). The Board adopted the Petitioner's broad definition of POSA in the field of thermal ablation systems.
Avanos Medical, Inc. v.Stratus Medical, LLC
The PTAB issued a Final Written Decision finding that Claims 1-17 and 48-52 are unpatentable based on obviousness. The Board found that the combination of prior art references (Racz, Fitz, Lee) was an obvious modification to create functional RF neurotomy devices.
Avanos Medical, Inc. v.Stratus Medical, LLC
The PTAB found that the claims were unpatentable over Racz, Fitz, and Lee based on obviousness (103). The Board adopted Petitioner's broad definition of 'thermal ablation systems,' rejecting the Patent Owner's narrow focus on 'RF neurotomy.'
Avanos Medical, Inc. v.Stratus Medical, LLC
The PTAB found all 29 challenged claims unpatentable by a preponderance of evidence. The Board rejected the Patent Owner's argument that the invention was limited to RF neurotomy, adopting Petitioner's broader view of 'thermal ablation systems.'
New Balance Athletics, Inc. v.Nike, Inc.
New Balance Athletics' IPR challenge against Nike's footwear patent was denied by the PTAB. The Board rejected arguments of anticipation and obviousness, particularly regarding claim scope limitations like 'article of footwear.'
Duration Media v.Rich Media Club LLC
The PTAB denied the institution of Inter Partes Review (IPR) against Rich Media Club LLC's advertising patent. The Board found that Petitioner Duration Media lacked a reasonable likelihood of prevailing on grounds of obviousness (103).
Inari Agriculture, Inc. v.Corteva Agriscience LLC et al.
Inari Agriculture successfully petitioned to institute an IPR against Corteva Agriscience's GMO patents based on prior art from Barbour. The Board found a reasonable likelihood of prevailing regarding anticipation and obviousness over the cited publication, moving the case toward trial.
Avanos Medical, Inc. v.Stratus Medical, LLC
Avanos Medical successfully petitioned to institute IPR proceedings against Stratus Medical's patent, demonstrating a reasonable likelihood of success on obviousness grounds. The Board found sufficient evidence that the claimed RF neurotomy features could be achieved by combining existing prior art references.
Avanos Medical, Inc. v.Stratus Medical, LLC
Avanos Medical, Inc. successfully convinced the PTAB to institute an IPR against Stratus Medical, LLC's '688 patent. The Board found a reasonable likelihood of success based on obviousness grounds (35 U.S.C. § 103) using prior art combinations like Racz and Lee.
Avanos Medical, Inc. v.Stratus Medical, LLC
Avanos Medical successfully navigated the institution phase of an IPR against Stratus Medical's RF neurotomy patent (10736688). The Board found a reasonable likelihood of success on multiple grounds, allowing the case to proceed to trial.
Avanos Medical, Inc. v.Stratus Medical, LLC
Avanos Medical successfully petitioned to institute an IPR against Stratus Medical regarding a neurotomy system patent (10925664). The Board found reasonable likelihood of success on the obviousness grounds, targeting claims 1-29.
Curio Bioscience et al. v.Prognosys Biosciences Inc. et al.
The PTAB denied the IPR petition brought by Curio Bioscience against Prognosys and 10X Genomics, finding that the challenged claims were not obvious over Cantor or anticipated by Frisen. The Board upheld the Patent Owner's position regarding spatial analysis in tissue samples.
Garmin International, Inc. et al. v.Saris Equipment, LLC
The PTAB granted institution for an IPR challenging Garmin's patent, finding a reasonable likelihood of unpatentability based on prior art anticipation and obviousness arguments against the '394 patent.
New Balance Athletics, Inc. v.Nike, Inc.
New Balance Athletics, Inc.'s IPR petition against Nike's footwear patent was denied by the PTAB. The Board found that Petitioner failed to demonstrate a reasonable likelihood of prevailing in its obviousness challenges over multiple prior art references.
Skechers U.S.A., Inc. v.Nike, Inc.
The PTAB denied Skechers' petition for IPR against Nike, finding that the petitioner failed to demonstrate material error regarding prior art already considered by the Examiner. This decision reinforces the strict application of the Advanced Bionics standard in discretionary denial proceedings.
Skechers U.S.A., Inc. v.Nike, Inc.
The PTAB institution of IPR2025-00141, filed by Skechers against Nike, moves forward to challenge the patent's validity on grounds of anticipation (102) and obviousness (103). The Board found that Petitioner demonstrated a reasonable likelihood of prevailing after vacating an initial discretionary denial.
Skechers U.S.A., Inc. v.Nike, Inc.
The PTAB denied institution of an IPR petition filed by Skechers against Nike, finding the claims lacked reasonable likelihood of prevailing based on obviousness grounds (103). The Board adopted the Patent Owner's narrow construction of 'article of footwear,' which was critical to the denial.
Skechers U.S.A., Inc. v.Nike, Inc.
Skechers' IPR challenge against Nike regarding knit textile footwear was denied by the PTAB. The Board found no reasonable likelihood of prevailing on obviousness grounds, despite adopting the patent owner's claim construction for 'article of footwear.'
Curio Bioscience, Inc. v.Prognosys Biosciences Inc. et al.
The PTAB denied Curio Bioscience's IPR challenge against Prognosys and 10X Genomics, finding no reasonable likelihood of prevailing on grounds of anticipation (102), obviousness (103), or written description (112). The Board upheld the validity of the challenged claims in spatial omics/assay systems technology.
Curio Bioscience, Inc. v.Prognosys Biosciences Inc. et al.
The PTAB denied Curio Bioscience's IPR against Prognosys/10X Genomics, finding no grounds for invalidity based on obviousness (Cantor/Armani) or anticipation (Frisen). The Board concluded that the prior art did not teach the necessary combination elements of spatially encoded biological assays.
Charles River Laboratories, Inc. v.Seikagaku Corporation
Charles River Laboratories successfully petitioned to invalidate Seikagaku Corporation's patent claims related to endotoxin detection. The Board found grounds for invalidity under 35 U.S.C. § 102 and § 112, specifically citing anticipation by a prior publication.
Solventum Corporation v.M.E.A.C. Engineering Ltd.
Solventum Corp. filed an IPR against M.E.A.C. Engineering’s patent 8,858,534. The parties settled before the Board could institute a trial, leading to a termination order.
Facing a similar IP matter?
Arctic Invent is a specialist IP firm with deep litigation expertise across India, EU, US, and UK. Our team uses data-driven strategy to build stronger cases.